BC
PLX icon

Broadfin Capital’s Protalix BioTherapeutics PLX Stock Holding History

Broadfin Capital’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-202,527
Closed -$1.3M – 71
2016
Q2 		$1.3M Sell
202,527
-136,102
-40% -$1.09M 0.13% 65
2016
Q1 		$2.85M Buy
338,629
+4,772
+1% +$40.9K 0.27% 62
2015
Q4 		$3.4M Buy
+333,857
New +$3.39M 0.21% 75

Other funds holding PLX

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Broadfin Capital's PLX Position: Q3 2016 in Review

Broadfin Capital sold out of Protalix BioTherapeutics (PLX) in Q3 2016, closing a stake of 202,527 shares — an estimated $1.3M sold.

Broadfin Capital first reported a position in PLX in Q4 2015 and held it in 3 quarters. The position peaked at $3.4M in Q4 2015. 29 funds tracked by Wall St. Rank hold PLX as of Q3 2016.

  • Broadfin Capital reported no remaining Protalix BioTherapeutics position as of Q3 2016 after selling out during the quarter.
  • Broadfin Capital sold 202,527 Protalix BioTherapeutics shares in Q3 2016, an estimated $1.3M.
  • Broadfin Capital first reported a position in Protalix BioTherapeutics in Q4 2015 and held it in 3 quarters.
  • Broadfin Capital's Protalix BioTherapeutics position peaked at $3.4M in Q4 2015.
  • 29 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2016.

Based on Broadfin Capital's 13F filing for Q3 2016, filed 14 Nov 2016.